Document is current

Article History

Received: 24 November 2024

Accepted: 18 March 2025

First Online: 21 April 2025

Declarations

:

: The study was performed according to the ethical principles of WMA Helsinki Declaration. The study was approved by the Human Research Ethics Committee of the Medical Faculty, University of Gothenburg (ethical approval number: 691-12, amendment number: T270-13). All patients signed a written informed consent before entering the study.

: Not applicable.

: AKE reports consulting fees from AbbVie, advisory board fees from Pfizer and AbbVie, speaker honorar from Boehringer Ingelheim and research grant from Aqilion. MLH reports Research Grant, institution: AbbVie, BMS, Eli Lilly, MSD, Pfizer, Sandoz, Novartis, Nordforsk, UCB. Institution: Pfizer, Medac, Sandoz, UCB. Institution and personal: Novartis. MLH has chaired the steering committee of the Danish Rheumatology Quality Registry (DANBIO, DRQ), which receives public funding from the hospital owners and funding from pharmaceutical companies. MLH co-chairs EuroSpA, which generates real-world evidence of treatment of psoriatic arthritis and axial spondylarthritis based on secondary data and is partly funded by Novartis. MØ has received research grants from AbbVie, Amgen, BMS, Merck, Celgene, Eli Lilly, Novartis, and UCB, speaker fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Galapagos, Gilead, Janssen, MEDAC, Merck, Novartis, Pfizer, Sandoz, and UCB, and consultancy fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Galapagos, Gilead, Hospira, Janssen, Merck, Novartis, Pfizer, Sandoz, and UCB. TU reports honorary payments for Galapagos, Lilly, Pfizer, UCB. DN reports consultant fees from Lilly, MSD, Novartis, Pfizer and UCB and research grant from MSD. RV reports Research Support (institutional grants): BMS, Support for Educational programs (institutional grants): Alfasigma, AstraZeneca, Galapagos, MSD, Novartis, Pfizer, Roche, Sanofi, UCB. Consultancy and/or speaker: AbbVie, AstraZeneca, Biogen, BMS, Galapagos, GSK, Janssen, Pfizer, RemeGen, UCB. All other authors declare no competing interest.